Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
financials
Pharma
Lilly blows out tirzepatide sales expectations, raises guidance
In the third quarter, sales of Lilly's obesity blockbuster Zepbound reached nearly $3.6 billion, growing a staggering 185% year over year.
Fraiser Kansteiner
Oct 30, 2025 10:39am
AstraZeneca plots NYSE listing amid UK industry pullback
Sep 29, 2025 10:05am
Sarepta extends $700M debt to 2030 amid Elevidys uncertainty
Aug 21, 2025 10:52am
Top 20 pharma companies by 2024 revenue
Apr 21, 2025 3:00am
J&J lifts 2025 sales guidance despite looming tariff threat
Apr 15, 2025 11:55am
Novartis unveils $23B investment to beef up US manufacturing, R&D
Apr 10, 2025 3:18pm
